🩸 Breakthrough in Multiple Myeloma Treatment! 🩺

🩸 Breakthrough in Multiple Myeloma Treatment! 🩺

LANCET

🔬Targeting GPRC5D with CAR-T Cells shows immense potential in treating relapsed or refractory multiple myeloma patients.
Multiple myeloma, a malignant disease characterized by clonal plasma cell proliferation in the bone marrow, has remained incurable despite substantial progress in treatment methods such as systemic chemotherapy, radiation therapy, and hematopoietic stem cell transplantation (HSCT). However, CAR-T cell therapy targeting B-cell maturation antigen (BCMA) has demonstrated activity in treating relapsed or refractory multiple myeloma. Nonetheless, the escape of BCMA-low or BCMA-negative myeloma cells has led to treatment resistance and relapse, highlighting the need to explore new targets.

💪In February 2023, a groundbreaking study titled “GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-center, single-arm, phase 1 trial” was published in The Lancet Haematology. The study aimed to evaluate the activity and safety of G-protein-coupled receptor class 5 member D (GPRC5D) CAR-T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma.

🌈Promising Treatment Response with OriCAR-017 Infusion
All ten patients (100%) demonstrated an overall response, with 6 patients (60%) achieving a complete response and 4 patients (40%) showing very good partial responses. The patients with complete responses met stringent complete response criteria, and all patients achieved minimal residual disease (MRD) negativity by day 28. Serum M-protein concentrations gradually decreased, and patients’ clinical responses improved over time. The median time to the best response was 3.1 months, while the median time to a complete response or better was 4.1 months.

☀️Among the 5 patients who relapsed after BCMA CAR-T cell therapy, 2 patients achieved a stringent complete response, and 3 patients showed very good partial responses. Four patients had extramedullary disease at enrollment, with the largest tumor volume measuring 70 cm³. PET-CT scans revealed complete resolution of extramedullary lesions in three patients, while the extramedullary disease in one patient continued to shrink. Furthermore, no severe adverse events or treatment-related deaths were reported.

🌱Favorable Survival Outcomes after OriCAR-017 Infusion
⏰The median follow-up time for all patients was 238 days, with two patients progressing after achieving stringent complete remission. One patient experienced GPRC5D-positive relapse, with GPRC5D expression in malignant plasma cells increasing from 34.5% at baseline to 35.8% at relapse. The other patient experienced GPRC5D-negative relapse, with GPRC5D expression in malignant plasma cells decreasing from 86.8% at baseline to 6.9% at relapse. The remaining eight patients in ongoing remission were all negative for minimal residual disease, and no deaths occurred. The median progression-free survival time was not reached, but the estimated progression-free survival rate for all patients at nine months was 87.5%.

🧬Durable CAR-T Cell Persistence
✨CAR-T cell expansion was detected in all patients after infusion, with a median time to maximum CAR-T cell expansion (Cmax) of 10.0 days and a median Cmax of 7930 copies/μl. CAR-T cells exhibited favorable persistence in the body, with CAR-T cells still detectable in 90% of patients at one month, seven patients at three months, and four patients at six months.

🌟 The study results demonstrate that targeting GPRC5D with CAR-T cells in treating relapsed or refractory multiple myeloma patients is safe and shows promising activity. The observed targeted and off-target toxicities associated with GPRC5D were manageable, indicating the potential of GPRC5D as an effective immunotherapeutic target for multiple myeloma. These findings provide a foundation for subsequent phase 2 studies to further validate the efficacy and safety of targeting GPRC5D CAR-T cells in multiple myeloma.🦾

We can help all international patients come to China to receive anticancer therapies such as CAR-T, TILs, and cancer vaccines.
We have access to medical resources from all cancer hospitals in China and can assist patients in receiving treatment from the best and top-tier oncologists in the CHINA.
doctor.huang@globecancer.com
WhatsApp+8613717959070

🔬 Stay tuned for more updates on this groundbreaking research! Together, we can conquer multiple myeloma!

#MultipleMyelomaResearch #CARTTherapy #GPRC5D #MedicalBreakthrough #cart #multiplemyeloma #chinesecart #cartcell #carttherapy #LANCET #Haematology #CARTCell

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

10 months ago CAR-T

China’s another cancer center launches an international medical department, offering comprehensive one-stop medical services to overseas patients

China’s another cancer center launches an international medical department, offering comprehensive one-stop medical services to overseas patients.

cancer center

The International Medical Department of Tongji Hospital,

    affiliated with Tongji University in Shanghai, has recently been officially launched. The department focuses on providing international medical services and aims to offer overseas patients a one-stop, seamless medical experience with high-quality and convenient healthcare services.

The advantages

    of the International Medical Department at Tongji Hospital go beyond providing one-stop, comprehensive medical services to overseas patients. It also means that overseas patients can receive a full range of medical services, from initial consultation to treatment and recovery, all in one place, without the need for frequent referrals or seeking treatment across multiple hospitals. The department is equipped with advanced facilities and equipment, including PET-CT scanners, linear accelerators (LA), high-end MRI and CT scanners, DSA machines, as well as integrated hybrid operating rooms, laparoscopic surgery systems, and 4K3D high-definition laparoscopes, providing patients with state-of-the-art diagnostic and treatment methods.

Furthermore, as another cancer center in China

    it offers the most advanced CAR-T cell therapy globally to all overseas patients. Tongji Hospital, well-known for its cancer treatment expertise in China, has accumulated rich experience and professional knowledge in the field of CAR-T cell therapy, enabling them to provide personalized and customized medical solutions for patients. The International Medical Department primarily serves high-end commercial insurance clients, foreign patients, overseas Chinese, diplomats and their families, and international corporate employees. The services provided by the department include initial consultation assessments, disease diagnosis, treatment plan development, surgeries and interventional therapies, rehabilitation, and follow-up care.

The medical team

    is the core strength of the department. The International Medical Department at Tongji Hospital has recruited a team of foreign physicians, clinical experts, and returning young doctors from Tongji Hospital, covering almost all clinical specialties. In addition, the department regularly invites internationally renowned experts to visit, such as Professor Kurt Fritzsch, a professor of psychosomatic medicine at the University of Freiburg in Germany, and Professor Claus Cursiefen, a professor of ophthalmology at the University of Cologne in Germany. Especially as a cancer center in China, Tongji Hospital also has a team with the highest number of CAR-T cancer treatment cases worldwide, ensuring the provision of top-quality medical services to patients.

If patients are interested in seeking treatment in China

    and staying at the International Medical Department of Tongji Hospital in Shanghai, or if they want to inquire about China’s cancer centers and the highest level of CAR-T therapy worldwide, the team at “Advanced medicine in China” will provide all the relevant services. These services include, but are not limited to, expert evaluations, online consultations with specialists, insurance service consultations, multilingual accompanying services, multilingual medical consultations and translation services, disease diagnosis, customized treatment plans, surgeries, interventional therapies, CAR-T treatments, hospitalization services, emergency rescue, referral services, medical companions, services for accompanying family members, and post-recovery guidance, among other value-added services, fully meeting the needs of patients.

WhatsApp: +86137 1795 9070

Email: doctor.huang@globecancer.com

#ChinaCancerCenter #InternationalMedicalServices #OneStopMedicalCare #TongjiHospital #AdvancedMedicine #CARTTherapy #MedicalExcellence #HighQualityHealthcare #CART #StateOfTheArtFacilities #SeamlessMedicalExperience #GlobalPatients #MultilingualServices #PersonalizedCare #RecoveryGuidance #MedicalTourism #HealthcareInChina #InternationalPatients #CuttingEdgeTechnology #ComprehensiveTreatment #TopMedicalExperts #GlobalHealthcare #MedicalBreakthroughs #HealthcareInnovation #PatientCare #MedicalAdvancements